Medecine et maladies infectieuses · 2020
Comparative review of imipenem/cilastatin versus meropenem.
Сравнительное исследованиеСтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Salmon-Rousseau A, Martins C, Blot M, Buisson M, Mahy S, Chavanet P, Piroth L
Аннотация
INTRODUCTION: Carbapenems are broad-spectrum antibacterial molecules. Imipenem-cilastatin and meropenem are the two main molecules used in French healthcare services.
OBJECTIVE: We aimed to evaluate the relative strengths and weaknesses of these two molecules by considering their pharmacokinetic, pharmacodynamic, microbiological, and clinical properties. We demonstrated that imipenem-cilastatin and meropenem are not alike.
METHOD: Review of the literature by querying the MEDLINE network.
RESULTS: Imipenem-cilastatin is the first marketed molecule of the carbapenem class. It is more effective against Gram-positive cocci. Its stability does not allow for long infusions and its main adverse effect on the central nervous system limits its use. Meropenem is more effective against Gram-negative bacilli. Its stability and its milder adverse effects distinguish it from imipenem-cilastatin.
CONCLUSION: Meropenem is preferred for daily use in healthcare services when carbapenems are to be used.
OBJECTIVE: We aimed to evaluate the relative strengths and weaknesses of these two molecules by considering their pharmacokinetic, pharmacodynamic, microbiological, and clinical properties. We demonstrated that imipenem-cilastatin and meropenem are not alike.
METHOD: Review of the literature by querying the MEDLINE network.
RESULTS: Imipenem-cilastatin is the first marketed molecule of the carbapenem class. It is more effective against Gram-positive cocci. Its stability does not allow for long infusions and its main adverse effect on the central nervous system limits its use. Meropenem is more effective against Gram-negative bacilli. Its stability and its milder adverse effects distinguish it from imipenem-cilastatin.
CONCLUSION: Meropenem is preferred for daily use in healthcare services when carbapenems are to be used.
Предметные рубрики MeSH
Anti-Bacterial AgentsBacterial InfectionsBiotransformationChildChild, PreschoolCilastatin, Imipenem Drug CombinationContraindications, DrugDrug Resistance, MicrobialDrug Resistance, Multiple, BacterialDrug StabilityFemaleGram-Negative BacteriaGram-Positive BacteriaHumansInfantLiver FailureMeropenemMolecular StructureOrgan SpecificityPregnancyPregnancy Complications, InfectiousProtein Binding